Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration
High-dose chemotherapy with autologous hematopoietic cell transplantation (AutoHCT) has long been an integral treatment modality for multiple myeloma and non-Hodgkin lymphoma. Over the past 25 years, numerous institutions have shifted this practice fro…